Anzeige
+++Starke Kurschance: Gamechanger-Meldung am späten Montagabend! Dienstagmorgen gleich ins Depot?+++

REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
18,15 EUR
-0,82 %-0,15
24. May, 08:42:37 Uhr, Lang & Schwarz
Kommentare 59
Summer.76
Summer.76, 4. Mai 22:19
0
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2022-financial-results-and-recent-operational-highlights-301540075.html
Summer.76
Summer.76, 2. Mär 5:53
0
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operational-highlights-301493248.html
Summer.76
Summer.76, 09.02.2022 19:06
0
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022 https://www.prnewswire.com/news-releases/regenxbio-presents-positive-initial-data-from-phase-iii-trial-of-rgx-111-for-the-treatment-of-severe-mps-i-at-18th-annual-worldsymposium-2022-301478817.html
Summer.76
Summer.76, 22.11.2021 14:46
0
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301429654.html
Summer.76
Summer.76, 12.11.2021 22:55
0
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-trials-of-rgx-314-in-wet-amd-and-diabetic-retinopathy-using-suprachoroidal-delivery-at-aao-2021-301423126.html
Summer.76
Summer.76, 12.11.2021 22:54
0
RegenxBio’s deal with AbbVie just closed. It could mean more than $1B for the local company. https://www.bizjournals.com/washington/news/2021/11/12/regenxbio-abbvie-close-deal-eye-disease-treatment.html RegenxBio Inc. has closed a massive development and commercialization deal with Chicago’s AbbVie Inc., two months after announcing the agreement that stands to shovel move than $1 billion to the Rockville biotech. The partners said Tuesday they have closed that transaction, to bring to market the local gene therapy company’s treatment candidate for multiple eye diseases, now in clinical trials for wet age-related macular degeneration (AMD), diabetic retinopathy and other chronic retinal illnesses. Now, AbbVie (NYSE: ABBV) pays RegenxBio (NASDAQ: RGNX) $370 million upfront. But the deal also carries the potential for an additional $1.38 billion in development, regulatory and commercial milestones. ...
Summer.76
Summer.76, 08.11.2021 19:32
0
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=847521
Summer.76
Summer.76, 02.11.2021 21:14
0
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2021-financial-results-and-operational-highlights-301414492.html
Summer.76
Summer.76, 02.11.2021 14:06
0
Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development https://seekingalpha.com/news/3762777-regenxbio-solid-biosciences-pdc-releases-white-paper-for-aav-gene-therapy-development ... The draft white paper proposes a framework that can be applied to AAV gene therapies to facilitate the use of the accelerated approval pathway at the U.S. FDA. ...
Summer.76
Summer.76, 11.10.2021 10:56
0
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting https://finance.yahoo.com/news/regenxbio-presents-positive-initial-data-152300587.html
Summer.76
Summer.76, 04.10.2021 19:19
0
https://seekingalpha.com/news/3748236-regenxbio-posts-biggest-intraday-loss-in-over-a-year-after-data-from-wet-amd-trial
Summer.76
Summer.76, 02.10.2021 8:20
0
https://www.biospace.com/article/releases/regenxbio-presents-positive-initial-data-from-phase-ii-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery-and-provides-trial-update-at-retina-society-54th-annual-scientific-meeting/
Summer.76
Summer.76, 27.09.2021 15:21
0
https://finance.yahoo.com/news/regenxbio-announces-rgx-314-data-110500392.html
Summer.76
Summer.76, 13.09.2021 16:51
0
Chardan Capital Stick to Their Buy Rating for RegenXBio https://www.investing.com/news/chardan-capital-stick-to-their-buy-rating-for-regenxbio-2614547
Summer.76
Summer.76, 13.09.2021 16:12
0
AbbVie and REGENXBIO Announce Eye Care Collaboration https://www.prnewswire.com/news-releases/abbvie-and-regenxbio-announce-eye-care-collaboration-301374836.html - AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise - Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases - REGENXBIO to receive $370 million upfront payment ...
Summer.76
Summer.76, 09.08.2021 22:14
0
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2021-financial-results-and-operational-highlights-301351442.html

Meistdiskutiert

Kommentare
1 Trading- und Aktien-Chat
2 VALNEVA SE Hauptdiskussion -1,01 %
3 BAVARIAN NORDIC Hauptdiskussion -3,53 %
4 für alle, die es ehrlich meinen beim Traden.
5 DAX Hauptdiskussion -1,17 %
6 Grassi's Meinungs und Tipp Forum
7 Exela Tech. nach RS -1,39 %
8 BTC/USD Hauptdiskussion -3,91 %
9 Dax Prognose -1,17 %
10 NIO INC.A S.ADR DL-,00025 Hauptdiskussion +0,78 %
Alle Diskussionen

Aktien

Kommentare
1 VALNEVA SE Hauptdiskussion -1,38 %
2 BAVARIAN NORDIC Hauptdiskussion -3,53 %
3 Exela Tech. nach RS -1,39 %
4 NIO INC.A S.ADR DL-,00025 Hauptdiskussion +0,81 %
5 DEUTSCHE BANK Hauptdiskussion -1,70 %
6 MS BioNTech -0,93 %
7 SNAP Hauptdiskussion -30,28 %
8 BRAINCHIP HOLDINGS LTD Hauptdiskussion -8,33 %
9 Plug Power 2222 +0,30 %
10 APPLE Hauptdiskussion -2,28 %
Alle Diskussionen
Werbung
Ihre kurzfristige Erwartung an RB0
RB0 steht am  bei
Veränderung:  
mgl. Rendite mit
Hebel (Omega)
Zum Produkt